Unknown

Dataset Information

0

Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024.

ABSTRACT: We estimated vaccine effectiveness (VE) of SARS-CoV-2 Omicron XBB.1.5 vaccination against self-reported infection between 9 October 2023 and 9 January 2024 in 23,895 XBB.1.5 vaccine-eligible adults who had previously received at least one booster. VE was 41% (95% CI: 23-55) in 18-59-year-olds and 50% (95% CI: 44-56) in 60-85-year-olds. Sequencing data suggest lower protection against the BA.2.86 (including JN.1) variant from recent prior infection (OR = 2.8; 95% CI:1.2-6.5) and, not statistically significant, from XBB.1.5 vaccination (OR = 1.5; 95% CI:0.8-2.6).

SUBMITTER: Huiberts AJ 

PROVIDER: S-EPMC10986669 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024.

Huiberts Anne J AJ   Hoeve Christina E CE   de Gier Brechje B   Cremer Jeroen J   van der Veer Bas B   de Melker Hester E HE   van de Wijgert Janneke Hhm JH   van den Hof Susan S   Eggink Dirk D   Knol Mirjam J MJ  

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 20240301 10

We estimated vaccine effectiveness (VE) of SARS-CoV-2 Omicron XBB.1.5 vaccination against self-reported infection between 9 October 2023 and 9 January 2024 in 23,895 XBB.1.5 vaccine-eligible adults who had previously received at least one booster. VE was 41% (95% CI: 23-55) in 18-59-year-olds and 50% (95% CI: 44-56) in 60-85-year-olds. Sequencing data suggest lower protection against the BA.2.86 (including JN.1) variant from recent prior infection (OR = 2.8; 95% CI:1.2-6.5) and, not statisticall  ...[more]

Similar Datasets

Unknown Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity - IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024.
| S-EPMC11177903 | biostudies-literature
Unknown Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023-January 2024.
| S-EPMC11325250 | biostudies-literature
Unknown JN.1 variants circulating in Italy from October 2023 to April 2024: genetic diversity and immune recognition.
| S-EPMC11871800 | biostudies-literature
Unknown Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS-CoV-2 Infection in Older Adults During the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023-1 March 2024.
| S-EPMC11551475 | biostudies-literature
Unknown 2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN).
| S-EPMC10986657 | biostudies-literature
Unknown Effectiveness of the 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 Vaccine (mRNA-1273.815) in Preventing COVID-19-related Hospitalizations and Medical Encounters Among Adults in the United States.
| S-EPMC11651145 | biostudies-literature
Unknown Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024.
| S-EPMC11890973 | biostudies-literature
Unknown Effectiveness of BNT162b2 XBB Vaccine Against XBB and JN.1 Sublineages.
| S-EPMC11250225 | biostudies-literature
Unknown XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1.
| S-EPMC10948033 | biostudies-literature
Unknown Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024.
| S-EPMC10853977 | biostudies-literature